Machine learning-enabled renal cell carcinoma status prediction using multi-platform urine-based metabolomics NMR (part-II)
Ontology highlight
ABSTRACT: Currently, Renal Cell Carcinoma (RCC) is identified through expensive cross-sectional imaging, frequently followed by renal mass biopsy, which is invasive and subject to sampling errors. Hence, there is a critical need for a non-invasive diagnostic assay. RCC is a disease of altered cellular metabolism with the tumor(s) in close proximity to the urine in the kidney suggesting metabolomic profiling would be an excellent choice for assay development. Here, we applied liquid chromatography-mass spectrometry (LC-MS), nuclear magnetic resonance (NMR), and machine learning (ML) for the discovery of candidate metabolic panels for RCC. The study cohort consists of 82 RCC patients and 174 healthy controls, these were separated into two sub-cohorts: model cohort and the test cohort. Discriminatory metabolic features were selected in the model cohort, using univariate, wrapper, and embedded methods of feature selection. Three ML techniques with different induction biases were used for training and hyperparameter tuning. Final assessment of RCC status prediction was made using the test cohort with the selected biomarkers and the tuned ML algorithms. A seven-metabolite panel consisting of endogenous and exogenous metabolites enabled the prediction of RCC with 88% accuracy, 94% sensitivity, and 85% specificity in the test cohort, with an AUC of 0.98.
ORGANISM(S): Human Homo Sapiens
TISSUE(S): Urine
DISEASE(S): Cancer
SUBMITTER: Olatomiwa Bifarin
PROVIDER: ST001706 | MetabolomicsWorkbench | Thu Feb 11 00:00:00 GMT 2021
REPOSITORIES: MetabolomicsWorkbench
ACCESS DATA